1,955 reports of this reaction
1.7% of all LEVETIRACETAM ORAL reports
#11 most reported adverse reaction
SOMNOLENCE is the #11 most commonly reported adverse reaction for LEVETIRACETAM ORAL, manufactured by Amneal Pharmaceuticals LLC. There are 1,955 FDA adverse event reports linking LEVETIRACETAM ORAL to SOMNOLENCE. This represents approximately 1.7% of all 117,347 adverse event reports for this drug.
Patients taking LEVETIRACETAM ORAL who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is a less commonly reported adverse event for LEVETIRACETAM ORAL, but still significant enough to appear in the safety profile.
In addition to somnolence, the following adverse reactions have been reported for LEVETIRACETAM ORAL:
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 1,955 FDA reports for LEVETIRACETAM ORAL. This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 1.7% of all adverse event reports for LEVETIRACETAM ORAL, making it a notable side effect.
If you experience somnolence while taking LEVETIRACETAM ORAL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.